STOCK TITAN

SAB BIOTHERAPEUTICS INC - SABS STOCK NEWS

Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.

Company Overview

SAB BIO (Nasdaq: SABS) is a clinical-stage biopharmaceutical company that employs a cutting-edge immunotherapy platform to develop human, multi-targeted, high-potency immunoglobulins (IgGs). As a pioneer in antibody science, the company utilizes its proprietary DiversitAb technology combined with transchromosomic (Tc) cattle to produce fully human polyclonal antibodies. This innovative approach avoids the reliance on human plasma or serum, thereby ensuring a consistent, scalable, and rapid production process that distinguishes SAB BIO from traditional biologics manufacturers.

At its core, SAB BIO is dedicated to addressing serious unmet medical needs in immune and autoimmune disorders, focusing primarily on type 1 diabetes (T1D). By harnessing advanced genetic engineering and a robust platform technology, the company aims to develop therapies that may delay the onset or progression of T1D and address other immune-related conditions. Strategic clinical programs, such as SAB-142—a human anti-thymocyte immunoglobulin—showcase the company’s commitment to generating innovative, disease-modifying solutions.

Innovative DiversitAb Platform

The DiversitAb platform is the heart of SAB BIO’s technology. It is designed to generate fully human polyclonal antibodies by leveraging transchromosomic cattle that have been genetically engineered to produce human antibodies instead of their bovine counterparts. This platform enables the rapid production of large quantities of targeted antibodies, ensuring both potency and specificity. The process not only represents a significant scientific breakthrough but also provides a reliable method to tackle a broad range of therapeutic areas without the typical constraints associated with donor-derived products.

Clinical Programs and Therapeutic Focus

SAB BIO’s lead asset, SAB-142, is a human anti-thymocyte immunoglobulin developed as a potential disease-modifying therapy for type 1 diabetes. Unlike conventional animal-derived therapies, SAB-142 is produced using the DiversitAb platform to offer a safer alternative with reduced risk of serum sickness and immunogenic reactions. The clinical development efforts, including rigorous pharmacokinetic, pharmacodynamic, and safety studies, underscore the company’s science-driven approach. This therapy is part of a broader portfolio aimed at providing multi-targeted solutions for various immune and autoimmune disorders.

Scientific Rigor and Operational Excellence

SAB BIO exemplifies expertise through its commitment to advanced antibody science and continuous innovation. The company collaborates with renowned clinical trial centers and partners in the biomedical space to conduct comprehensive trials that test not only the safety and tolerability of its products but also their potential biological activity. Each phase in clinical testing reinforces the credibility of the data and ensures adherence to the highest standards of research integrity, reinforcing the company’s position as a reliable and authoritative figure in the biopharmaceutical industry.

Market Position and Competitive Landscape

In the competitive landscape of biopharmaceutical development, SAB BIO differentiates itself through its unique DiversitAb platform and its focus on fully human biologics. The company’s approach to generating targeted polyclonal antibodies circumvents the limitations associated with traditional donor-based methods. This technological advantage positions SAB BIO as a notable innovator among peers, drawing attention from clinical experts, strategic partners, and investors who seek scientifically validated and rigorously studied immunotherapies.

Commitment to Transparency and Expertise

Each step of SAB BIO’s development is underpinned by a commitment to transparency, scientific rigor, and operational excellence. The company’s detailed clinical updates and thorough preclinical studies provide stakeholders with clear insights into its therapeutic pipeline and technological methodologies. By integrating industry-specific terminology with an accessible narrative, SAB BIO communicates its value proposition effectively, ensuring that both seasoned investors and those new to the biopharmaceutical sector can appreciate the depth and significance of its innovations.

Conclusion

Overall, SAB BIO represents a unique convergence of innovative science and strategic clinical focus. Its proprietary immunotherapy platform offers a groundbreaking method for producing fully human polyclonal antibodies, establishing a new paradigm in the treatment of type 1 diabetes and other immune-related disorders. The company’s fact-based, unbiased outlook is rooted in a commitment to excellence in research, operational transparency, and continuous scientific innovation, making it a subject of significant interest for those involved in the biopharmaceutical field.

Rhea-AI Summary

SAB Biotherapeutics will present at the Large Animal Genetic Engineering Summit on June 7, 2022, in Park City, Utah. CEO Dr. Christoph Bausch will discuss advancements in their Transchromosomic (Tc) Goat platform for producing fully human polyclonal antibodies. The presentation will cover the DiversitAb platform, highlighting pipeline programs including SAB-185 (anti-SARS-CoV-2), SAB-176 (influenza), and SAB-142 (Type 1 diabetes). The company focuses on innovative immunotherapy solutions aimed at serious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
conferences
-
Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) reported its Q1 2022 financial results and company updates, emphasizing significant advancements in its immunotherapy platform.

Key highlights include:

  • Cash and cash equivalents of $22.4 million as of March 31, 2022.
  • R&D expenses increased to $13.3 million, attributed to expanded capabilities.
  • Net income was $1 million, equating to $0.02 per share.

Full data from the Phase 2a trial for SAB-176 is expected in Q3 2022, with additional updates on SAB-185 and other pipeline candidates anticipated later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.17%
Tags
-
Rhea-AI Summary

SAB Biotherapeutics (NASDAQ: SABS) will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company's management team is scheduled for a live Fireside Chat on May 25, 2022, at 9:00 am EDT. An on-demand webcast will be available on their website, allowing investors to access the presentation for 90 days post-event. SAB Biotherapeutics focuses on developing immunotherapies using fully human polyclonal antibodies for various diseases, including COVID-19 and type 1 diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences
Rhea-AI Summary

SAB Biotherapeutics has appointed Dr. Mark J. Ratain to its Board of Scientific Advisors to enhance its oncology platform. Dr. Ratain, a prominent expert in cancer treatment and clinical pharmacology, has published over 500 academic works and will contribute his extensive knowledge to advance SAB's fully-human polyclonal antibody therapies.

CEO Eddie J. Sullivan expressed enthusiasm about Dr. Ratain's addition, emphasizing the potential benefits for the company’s targeted multivalent immunotherapies aimed at treating cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.8%
Tags
management
-
Rhea-AI Summary

SAB Biotherapeutics reported significant progress in 2021, highlighted by the closing of its business combination and listing on NASDAQ. The company is advancing its pipeline of polyclonal antibodies, including SAB-185 for COVID-19 and SAB-176 for influenza, with initial data expected mid-2022. SAB's Rapid Response Antibody Program, in collaboration with the US Department of Defense, is also ongoing. With cash reserves of $33.2 million and additional government funding expected, SAB anticipates sufficient resources to support operations through Q3 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.56%
Tags
-
Rhea-AI Summary

SAB Biotherapeutics announced the discontinuation of patient enrollment in the NIH’s ACTIV-2 Phase 3 COVID-19 trial due to low hospitalization and death rates, which rendered the study statistically unworkable. Despite SAB-185 achieving pre-specified efficacy and safety criteria, the Data and Safety Monitoring Board deemed it operationally futile to continue the study. SAB Biotherapeutics is now exploring future clinical plans for SAB-185, targeting high-risk populations for prophylactic and therapeutic applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.87%
Tags
clinical trial covid-19
Rhea-AI Summary

SAB Biotherapeutics announced significant findings regarding SAB-185, a fully-human polyclonal antibody candidate targeting SARS-CoV-2. The nonclinical data, part of a study conducted with the FDA, reveals that SAB-185 exhibits strong neutralizing capabilities against several COVID-19 variants, including Delta, and outperforms convalescent plasma. These results, published in The Journal of Infectious Diseases, suggest SAB-185's potential as an effective therapy for high-risk COVID-19 patients. The antibody is currently being tested in the NIH's Phase 3 ACTIV-2 trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.87%
Tags
-
Rhea-AI Summary

SAB Biotherapeutics updates its Phase 3 ACTIV-2 trial for SAB-185, now pivoting to a placebo-controlled design to evaluate its efficacy against the Omicron variant of COVID-19. The trial, sponsored by the NIAID, will include an additional 800 participants, bringing the total to approximately 1,200. SAB-185 demonstrates neutralizing activity against COVID variants, including Omicron. The trial's design change reflects the need for effective treatments as Omicron now comprises about 95% of new cases in the US, aiming to restart data collection with minimal disruption.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
clinical trial covid-19
-
Rhea-AI Summary

SAB Biotherapeutics reported positive advancements for SAB-185, a fully-human polyclonal antibody for treating high-risk non-hospitalized COVID-19 patients, now in Phase 3 of the NIH-sponsored ACTIV-2 trial. Following a favorable DSMB review of Phase 2 data, over 700 patients have been enrolled, exceeding half of the 1,200 target. SAB-185 demonstrated significant viral load reductions in a small subset of high-risk patients, indicating potential efficacy. However, statistical significance was limited due to the protocol shift towards lower-risk participants in earlier phases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.13%
Tags
clinical trial covid-19
Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) announced that co-founder and CEO Eddie J. Sullivan, PhD, will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation will be available for on-demand viewing starting January 10 at 7:00 a.m. ET. SAB focuses on developing novel immunotherapies using fully-human polyclonal antibodies, targeting various diseases, including infectious diseases and cancer. Their DiversitAb™ platform aims to meet serious unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
conferences

FAQ

What is the current stock price of SAB BIOTHERAPEUTICS (SABS)?

The current stock price of SAB BIOTHERAPEUTICS (SABS) is $1.11 as of April 7, 2025.

What is the market cap of SAB BIOTHERAPEUTICS (SABS)?

The market cap of SAB BIOTHERAPEUTICS (SABS) is approximately 10.6M.

What is SAB BIO?

SAB BIO is a clinical-stage biopharmaceutical company that develops human immunotherapies using its innovative DiversitAb platform. It focuses on producing fully human polyclonal antibodies for the treatment of immune and autoimmune disorders.

How does the DiversitAb platform work?

The DiversitAb platform leverages genetically engineered transchromosomic cattle to produce fully human polyclonal antibodies. This method bypasses the need for human plasma and allows for rapid, scalable production of targeted antibodies.

What therapeutic areas does SAB BIO focus on?

SAB BIO focuses primarily on immune and autoimmune disorders, with a significant emphasis on type 1 diabetes. Its pipeline includes therapies aimed at modifying disease progression by targeting specific immune cells.

What is SAB-142?

SAB-142 is a human anti-thymocyte immunoglobulin developed using SAB BIO's DiversitAb platform. It is designed as a disease-modifying therapy for type 1 diabetes, aiming to delay disease onset and progression while offering an improved safety profile.

How is SAB-142 different from traditional therapies?

Unlike traditional therapies that use animal-derived antibodies, SAB-142 is fully human, reducing the risk of serum sickness and adverse immune reactions. This difference is achieved through the company’s innovative antibody production technology.

Who can benefit from SAB BIO's therapies?

Patients suffering from immune and autoimmune disorders, particularly those with type 1 diabetes, may benefit from SAB BIO's advanced immunotherapy solutions. The therapies are designed to provide targeted treatment with a strong safety profile.

What makes SAB BIO stand out in the biopharmaceutical industry?

SAB BIO stands out due to its proprietary DiversitAb platform, which enables the rapid production of fully human antibodies via genetically engineered transchromosomic cattle. This technological innovation provides a unique advantage in developing effective and safe biologic therapies.

How does SAB BIO ensure the safety and efficacy of its products?

The company conducts rigorous clinical trials and collaborates with established research centers to evaluate the safety, tolerability, and pharmacodynamic profiles of its products. Detailed clinical studies and transparent reporting help maintain high standards of scientific integrity.
SAB BIOTHERAPEUTICS INC

Nasdaq:SABS

SABS Rankings

SABS Stock Data

10.61M
7.53M
19.15%
28.69%
1.35%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MIAMI BEACH